Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
301-02-002 ISMRM Abstract

The Role of DCE-MRI in Distinguishing Metastatic from Non-Metastatic Lymph Nodes in Rectal Cancer

Primary: Body - Digestive
Secondary: Contrast Mechanisms - Perfusion
301-02-002 · Advances in Rectum and Pelvis MRI · Monday, 11 May, 8:20 AM–10:10 AM · Hall 1A
Keywords: Rectal cancer DCE-MRI Lymph node
Accepted
Wen-jie Fan 1, Yan Chen2, Yunzhu Wu3, Xiao-chun Meng1, Shen-ping Yu2
1The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
2The First Affiliated Hospital, Sun Yat-sen University, China
3MR Research Collaboration Team, Shanghai, China
Presenting Author: Wen-jie Fan

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, et al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(10):1139–67.
2. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42.
3. Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37(34):3212–22.
4. Zhang Y, Brand D, Shen Z, Simard M, Hindocha S, Chohan O, et al. Predicting acute diarrhoea in rectal cancer chemoradiotherapy: Secondary analysis of the phase III ARISTOTLE trial. Radiother Oncol. 2025;210:111032.
5. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. J Clin Oncol. 2005;23(25):6199–206.
6. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10(3):223–32.
7. Yang X, Chen Y, Wen Z, Lu B, Shen B, Xiao X, et al. Role of Quantitative Dynamic Contrast-Enhanced MRI in Evaluating Regional Lymph Nodes With a Short-Axis Diameter of Less Than 5 mm in Rectal Cancer. AJR Am J Roentgenol. 2019;212(1):77–83.
8. Goh V, Padhani AR, Rasheed S. Functional imaging of colorectal cancer angiogenesis. Lancet Oncol. 2007;8(3):245–55.

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/301-02-002